NASDAQ:ACER

Acer Therapeutics Stock Forecast, Price & News

$2.60

0.00 (0.00 %)

(As of 11/27/2020 12:00 AM ET)

Add

Compare

Today's Range

$2.52

Now: $2.60▼

$2.65

50-Day Range

$2.44

MA: $2.75▼

$2.96

52-Week Range

$1.08

Now: $2.60▼

$7.25

Volume75,600 shs

Average Volume227,924 shs

Market Capitalization$31.94 million

P/E RatioN/A

Dividend YieldN/A

Beta1.81

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of induced Vasomotor Symptoms. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Acer Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Acer Therapeutics has a forecasted upside of 284.6% from its current price of $2.60.
Amount of Analyst Coverage
Acer Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Acer Therapeutics has received 285 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Acer Therapeutics has received 243 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Acer Therapeutics has received 53.98% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote “Outperform” if you believe ACER will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Acer Therapeutics does not currently pay a dividend.
Dividend Growth
Acer Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acer Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 19.90% of the stock of Acer Therapeutics is held by insiders.
Percentage Held by Institutions
Only 16.25% of the stock of Acer Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Acer Therapeutics are expected to grow in the coming year, from ($1.97) to ($1.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acer Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acer Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acer Therapeutics has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.33 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ACER

Previous Symbol

CUSIPN/A

CIK1069308

Webwww.acertx.com

Phone844-902-6100

Employees20

Debt

Debt-to-Equity RatioN/A

Current Ratio1.56

Quick Ratio1.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.86 per share

Price / Book3.02

Profitability

EPS (Most Recent Fiscal Year)($2.91)

Net Income$-29,420,000.00

Net MarginsN/A

Return on Equity-160.97%

Return on Assets-128.71%

Miscellaneous

Outstanding Shares12,285,000

Market Cap$31.94 million

Next Earnings Date3/17/2021 (Estimated)

OptionableNot Optionable

$2.60

0.00 (0.00 %)

(As of 11/27/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

How has Acer Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACER stock has decreased by 23.1% and is now trading at $2.60.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Acer Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Acer Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Acer Therapeutics?

Wall Street analysts have given Acer Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Acer Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for Acer Therapeutics.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc. (NASDAQ:ACER) released its quarterly earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.05.
View Acer Therapeutics' earnings history.

What price target have analysts set for ACER?

3 analysts have issued 1-year price targets for Acer Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Acer Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 284.6% from the stock's current price.
View analysts' price targets for Acer Therapeutics.

Who are some of Acer Therapeutics' key competitors?

Some companies that are related to Acer Therapeutics include Adamas Pharmaceuticals (ADMS), Lumos Pharma (LUMO), Genprex (GNPX), Equillium (EQ), Spring Bank Pharmaceuticals (SBPH), Xynomic Pharmaceuticals (XYNO), Antibe Therapeutics (ATBPF), Orgenesis (ORGS), Sio Gene Therapies (SIOX), Cocrystal Pharma (COCP), Enlivex Therapeutics (ENLV), Immunome (IMNM), Oncolytics Biotech (ONCY), Aytu BioScience (AYTU) and PhaseBio Pharmaceuticals (PHAS).
View all competitors.

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:

Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 44, Pay $436k)
Mr. Harry S. Palmin, COO & CFO (Age 50, Pay $382.4k)
Mr. John Michael Klopp, Chief Technical Officer (Age 45)
Mr. Donald R. Joseph J.D., Chief Legal Officer & Sec. (Age 66)
Mr. Bernie Paul, VP of HR
Mr. Matthew T. Seibt, Chief Commercial Officer (Age 49)
Mr. Jason Kneeland CPA, VP of Fin. & Controller

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (2.04%), Federated Hermes Inc. (0.99%), BlackRock Inc. (0.79%), GSA Capital Partners LLP (0.69%) and State Street Corp (0.11%). Company insiders that own Acer Therapeutics stock include Chris Schelling, Donald Joseph and Steve Aselage.
View institutional ownership trends for Acer Therapeutics.

Which institutional investors are selling Acer Therapeutics stock?

ACER stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Federated Hermes Inc., and State Street Corp.
View insider buying and selling activity for Acer Therapeutics.

Which institutional investors are buying Acer Therapeutics stock?

ACER stock was acquired by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC, and GSA Capital Partners LLP. Company insiders that have bought Acer Therapeutics stock in the last two years include Chris Schelling, Donald Joseph, and Steve Aselage.
View insider buying and selling activity for Acer Therapeutics.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $2.60.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $31.94 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 20 workers across the globe.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is www.acertx.com.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings